Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) announced that its CEO, Jean-Pierre Sommadossi, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET. The presentation will include insights into Atea's focus on developing oral therapeutics for severe viral infections, particularly for ssRNA viruses like SARS-CoV-2, the virus causing COVID-19. A live webcast of the event can be accessed here. A replay will be available for 90 days.

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.  

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

FAQ

When will Atea Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?

Atea Pharmaceuticals will present on June 2, 2021, at 2:30 p.m. ET.

Who is presenting for Atea Pharmaceuticals at the Jefferies Conference?

Jean-Pierre Sommadossi, the CEO of Atea Pharmaceuticals, will present.

What is Atea Pharmaceuticals focusing on developing?

Atea Pharmaceuticals is focused on developing oral therapeutics for severe viral infections, especially those caused by ssRNA viruses.

How can I access the Atea Pharmaceuticals presentation?

The presentation will be available via a live webcast on Atea's website and can be accessed here.

What types of viral infections is Atea Pharmaceuticals targeting?

Atea Pharmaceuticals is targeting infections caused by ssRNA viruses, including SARS-CoV-2, dengue virus, hepatitis C virus, and respiratory syncytial virus.